• Publications
  • Influence
Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress.
Many different systems and strategies have been evaluated for drug targeting to tumors over the years. Routinely used systems include liposomes, polymers, micelles, nanoparticles and antibodies, andExpand
  • 917
  • 31
  • PDF
Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system
An overview of recent advances in the surface modification of colloidal particles to oppose uptake by the mononuclear phagocyte system (MPS) is presented. First, we describe the colloidal particlesExpand
  • 768
  • 20
Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle.
Potent sequence selective gene inhibition by siRNA 'targeted' therapeutics promises the ultimate level of specificity, but siRNA therapeutics is hindered by poor intracellular uptake, limited bloodExpand
  • 837
  • 18
  • PDF
Endosomal escape pathways for delivery of biologicals.
Despite continuous improvements in delivery systems, the development of methods for efficient and specific delivery of targeted therapeutic agents still remains an issue in biological treatments suchExpand
  • 947
  • 15
Factors affecting the accelerated blood clearance of polyethylene glycol-liposomes upon repeated injection.
Previously, we showed that long-circulating polyethylene glycol (PEG)-liposomes are cleared rapidly from the circulation when injected repeatedly in the same animal. In this article, we describe theExpand
  • 241
  • 12
  • PDF
Complete remission of experimental arthritis by joint targeting of glucocorticoids with long-circulating liposomes.
OBJECTIVE To increase the therapeutic activity of glucocorticoids in experimental arthritis by encapsulation in long-circulating polyethylene glycol liposomes, which have shown the ability toExpand
  • 235
  • 11
Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes.
Sterically stabilized liposomes are considered promising carriers of therapeutic agents because they can facilitate controlled release of the drugs, thereby reducing drug-related toxicity and/orExpand
  • 378
  • 10
  • PDF
Liposomes: quo vadis?
Abstract Liposomes have matured as a delivery system for therapeutic agents. It has taken two decades to develop the liposome carrier concept to a pharmaceutical product level, but commercialExpand
  • 221
  • 10
Challenges and strategies in anti-cancer nanomedicine development: An industry perspective.
Successfully translating anti-cancer nanomedicines from pre-clinical proof of concept to demonstration of therapeutic value in the clinic is challenging. Having made significant advances with drugExpand
  • 475
  • 9
Lymphatic uptake and biodistribution of liposomes after subcutaneous injection. II. Influence of liposomal size, lipid compostion and lipid dose.
The present paper reports on the results of a systematic study on liposome variables potentially affecting lymphatic disposition and biodistribution of liposomes after sc injection. Liposomal sizeExpand
  • 277
  • 8